Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Brokers Extension For Golimumab Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

Under agreement with co-developer Centocor, Schering will have exclusive worldwide marketing rights 15 years beyond expected launch date.

You may also be interested in...



J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue

Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.

J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue

Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.

J&J Could File “New Gold Standard” In Anti-TNF Therapy By Late 2007

CNTO 148 is in Phase III for RA, ankylosing spondylitis and psoriatic arthritis.

Related Content

Topics

UsernamePublicRestriction

Register

PS064698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel